Aethlon Days Payables Outstanding vs Ev To Operating Cash Flow Analysis
AEMD Stock | USD 0.58 0.15 34.88% |
Aethlon Medical financial indicator trend analysis is way more than just evaluating Aethlon Medical prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aethlon Medical is a good investment. Please check the relationship between Aethlon Medical Days Payables Outstanding and its Ev To Operating Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aethlon Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Aethlon Stock refer to our How to Trade Aethlon Stock guide.
Days Payables Outstanding vs Ev To Operating Cash Flow
Days Payables Outstanding vs Ev To Operating Cash Flow Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aethlon Medical Days Payables Outstanding account and Ev To Operating Cash Flow. At this time, the significance of the direction appears to have very week relationship.
The correlation between Aethlon Medical's Days Payables Outstanding and Ev To Operating Cash Flow is 0.28. Overlapping area represents the amount of variation of Days Payables Outstanding that can explain the historical movement of Ev To Operating Cash Flow in the same time period over historical financial statements of Aethlon Medical, assuming nothing else is changed. The correlation between historical values of Aethlon Medical's Days Payables Outstanding and Ev To Operating Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Days Payables Outstanding of Aethlon Medical are associated (or correlated) with its Ev To Operating Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Operating Cash Flow has no effect on the direction of Days Payables Outstanding i.e., Aethlon Medical's Days Payables Outstanding and Ev To Operating Cash Flow go up and down completely randomly.
Correlation Coefficient | 0.28 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Days Payables Outstanding
Ev To Operating Cash Flow
A valuation metric comparing the company's enterprise value to its operating cash flow, indicating how many dollars of EV are generated for each dollar of operating cash flows.Most indicators from Aethlon Medical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aethlon Medical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aethlon Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Aethlon Stock refer to our How to Trade Aethlon Stock guide.At present, Aethlon Medical's Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.01, whereas Sales General And Administrative To Revenue is forecasted to decline to 6.30.
Aethlon Medical fundamental ratios Correlations
Click cells to compare fundamentals
Aethlon Medical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Aethlon Medical fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 10.4M | 10.7M | 19.4M | 17.5M | 8.2M | 8.7M | |
Other Current Liab | 584.1K | 880.2K | 852.6K | 802.8K | 761.5K | 723.4K | |
Total Current Liabilities | 1.1M | 1.4M | 1.8M | 1.5M | 1.8M | 2.8M | |
Total Stockholder Equity | 9.4M | 9.4M | 17.1M | 15.1M | 5.8M | 6.1M | |
Net Debt | (9.5M) | (9.8M) | (16.3M) | (13.3M) | (4.5M) | (4.3M) | |
Retained Earnings | (112.0M) | (119.9M) | (130.3M) | (142.4M) | (154.6M) | (146.8M) | |
Cash | 9.6M | 9.9M | 17.1M | 14.5M | 5.4M | 3.0M | |
Non Current Assets Total | 346.6K | 317.2K | 1.3M | 2.4M | 2.3M | 2.4M | |
Cash And Short Term Investments | 9.6M | 9.9M | 17.1M | 14.5M | 5.4M | 3.0M | |
Common Stock Total Equity | 17.7K | 19.0K | 9.4K | 12.2K | 14.0K | 13.3K | |
Common Stock Shares Outstanding | 341.5K | 1.2M | 1.5M | 2.1M | 2.5M | 2.6M | |
Liabilities And Stockholders Equity | 10.4M | 10.7M | 19.4M | 17.5M | 8.2M | 8.7M | |
Other Stockholder Equity | 121.4M | 129.3M | 147.4M | 157.4M | 160.3M | 168.4M | |
Total Liab | 1.1M | 1.4M | 2.4M | 2.4M | 2.5M | 4.1M | |
Total Current Assets | 10.0M | 10.4M | 18.2M | 15.1M | 5.9M | 3.2M | |
Common Stock | 9.4K | 12.2K | 15.4K | 23.0K | 2.6K | 2.5K | |
Property Plant And Equipment Net | 276.9K | 201.3K | 1.1M | 2.3M | 1.9M | 2.0M | |
Accounts Payable | 285.0K | 337.7K | 500.0K | 432.9K | 777.9K | 566.0K | |
Property Plant And Equipment Gross | 276.9K | 201.3K | 1.1M | 2.3M | 2.9M | 3.0M | |
Intangible Assets | 57.5K | 57.0K | 2.2K | 1.7K | 1.1K | 1.0K | |
Short Long Term Debt Total | 141.1K | 42.5K | 729.4K | 1.2M | 940.3K | 949.8K | |
Other Current Assets | 229.6M | 341.1K | 1.9M | 557.6K | 506.0K | 480.7K | |
Accumulated Other Comprehensive Income | (368.3K) | (385.5K) | 0.0 | (6.1M) | (6.9K) | (7.3K) | |
Short Term Debt | 98.6K | 42.5K | 126.9K | 269.4K | 290.6K | 276.0K | |
Property Plant Equipment | 140.5K | 201.3K | 1.1M | 2.3M | 2.6M | 2.8M | |
Non Current Liabilities Total | 42.5K | 495.1K | 602.5K | 939.6K | 649.8K | 544.9K | |
Net Tangible Assets | 9.4M | 9.4M | 17.1M | 15.1M | 17.3M | 18.2M | |
Noncontrolling Interest In Consolidated Entity | (101.2K) | (126.0K) | (132.1K) | (136.9K) | (123.2K) | (117.1K) | |
Retained Earnings Total Equity | (99.5M) | (105.7M) | (112.0M) | (119.9M) | (107.9M) | (113.3M) | |
Capital Surpluse | 105.6M | 108.1M | 121.4M | 129.3M | 148.7M | 97.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Aethlon Medical is a strong investment it is important to analyze Aethlon Medical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aethlon Medical's future performance. For an informed investment choice regarding Aethlon Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aethlon Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Aethlon Stock refer to our How to Trade Aethlon Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aethlon Medical. If investors know Aethlon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aethlon Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.79) | Revenue Per Share 0.236 | Quarterly Revenue Growth 42.782 | Return On Assets (0.50) | Return On Equity (1.05) |
The market value of Aethlon Medical is measured differently than its book value, which is the value of Aethlon that is recorded on the company's balance sheet. Investors also form their own opinion of Aethlon Medical's value that differs from its market value or its book value, called intrinsic value, which is Aethlon Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aethlon Medical's market value can be influenced by many factors that don't directly affect Aethlon Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aethlon Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Aethlon Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aethlon Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.